Serum

Garnier Unveils Their Most Innovative Haircare Launch To-Date with Fructis Hair Filler Collections

Retrieved on: 
Wednesday, February 28, 2024
Cream, Social media, Collection, Diving, Senior, Marketing, Partnership, Public key certificate, Exosphere, Advertising, Walmart, Ulta, Graffiti, Target, Ceramide, CVS, Drawing, Amazon, Science, Serum, Charli, Cosmetics

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Garnier Fructis, a key player in the mass haircare space, is taking strides to provide professional-strength technology that reverses up to one year of visible damage in one use with the launch of the Garnier Fructis Hair Filler product line. Inspired by the power of skin fillers, the launch showcases both hair repair science and robust marketing support—a clear signal of Garnier's commitment to providing innovative solutions for diverse hair needs.

Key Points: 
  • To launch Fructis Hair Filler, Garnier is engaging TikTok phenomenon, television personality, and entrepreneur, Charli D'Amelio , for a content series diving into product nuances and science-backed technology.
  • The Fructis Hair Filler collection is poised to elevate the haircare experience for consumers worldwide, bringing salon-worthy results to the comfort of their homes.
  • The Fructis Hair Filler line consists of three collections: Strength Repair with Vitamin Cg, Moisture Repair with Hyaluronic, and Color Repair with Ceramide.
  • For the launch of Fructis Hair Filler range, Garnier created an innovative customer experience in store, developed in partnership with Graffiti, a breakthrough AI-based start-up.

GeminiBio launches human serum AB product for global cell therapy market

Retrieved on: 
Monday, February 26, 2024
AB, Serum, US FDA, European, History, Bone marrow, Leukemia, Plasma, Male, CGMP, Lymphoma, Research, Vaccine

WEST SACRAMENTO, Calif., Feb. 26, 2024 /PRNewswire/ -- Gemini Bioproducts, LLC ("GeminiBio"), a leading supplier of cell culture reagents and process liquids, a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, today announced the launch of a new human AB serum product for the cell therapy and regenerative medicine markets.

Key Points: 
  • WEST SACRAMENTO, Calif., Feb. 26, 2024 /PRNewswire/ -- Gemini Bioproducts, LLC ("GeminiBio"), a leading supplier of cell culture reagents and process liquids, a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, today announced the launch of a new human AB serum product for the cell therapy and regenerative medicine markets.
  • GeminiBio has an extensive history supporting the cell therapy research and development market, offering a portfolio of human serum products which are generally used in a growth medium for cell therapy biotechnologies such as chimeric antigen receptor T cell (CAR-T) therapies.
  • As the cell therapy market has matured, including the successful US FDA approval of CAR-T therapies targeting blood cancers such as leukemia and lymphoma, the company has worked closely with customers to address evolving global regulatory requirements pertaining to ancillary products, such as human AB serum, used in the cell therapy manufacturing process.
  • To further support regulatory requirements in different regions around the world, GeminiBio is introducing a new human AB serum – GemCellTM Plus Xeno Free, World Grade.

Delavie Sciences Aeonia™ Unveils New Product Specifically For Sensitive Skin

Retrieved on: 
Tuesday, February 20, 2024
Elasticity, Doctor of Philosophy, Ageing, Extremophile, Harvard University, Skin, Radical, Skin care, Red, Hyaluronic acid, Clinical trial, Longevity, Serum, Research, Irritation

This delicate version is uniquely made as a unique formulation of the best-selling Age Defying Serum and is intended for use by those diagnosed with sensitive skin.

Key Points: 
  • This delicate version is uniquely made as a unique formulation of the best-selling Age Defying Serum and is intended for use by those diagnosed with sensitive skin.
  • The Aeonia™ Gentle Age Defying Serum is clinically proven to hydrate the skin while decreasing the appearance of fine lines and wrinkles.
  • The proprietary formulation absorbs quickly and easily into the skin^, making the skin appear healthier and more youthful.
  • "We continue to push the boundaries of skin care while ensuring that even those with the most sensitive skin can benefit from our exclusive, patented ingredients.

COSRX Celebrates the Return of The 6 Peptide Skin Booster Serum - A Derm-Favorite Now Back in Stock at Ulta

Retrieved on: 
Friday, February 16, 2024
Cream, Gland, Peptide, Vitamin, Skin, Serum, Hyperpigmentation, Cosmetics

LOS ANGELES, Feb. 16, 2024 /PRNewswire/ -- COSRX, the beloved beauty brand known for its derm-favourite skincare solutions, is delighted to announce the return of the COSRX The 6 Peptide Skin Booster Serum at Ulta.

Key Points: 
  • LOS ANGELES, Feb. 16, 2024 /PRNewswire/ -- COSRX, the beloved beauty brand known for its derm-favourite skincare solutions, is delighted to announce the return of the COSRX The 6 Peptide Skin Booster Serum at Ulta.
  • The exceptional popularity of The 6 Peptide Skin Booster Serum can be attributed to its unique blend of six peptides which works wonders in addressing various skin concerns, making it the go-to solution for anyone seeking perfect skin.
  • COSRX recommends incorporating The 6 Peptide Skin Booster Serum as the first step of one's skincare routine.
  • "We are delighted to bring back The 6 Peptide Skin Booster Serum to Ulta after its remarkable success," said a spokesperson for COSRX.

Indeed Labs Launches Nanobronze™ Deep: Bronzing Drops for Deeper Skin Tones

Retrieved on: 
Thursday, February 8, 2024
Elasticity, Skin, Shoppers Drug Mart, Red, Face, Ulta, Serum, Bronzing, Cosmetics

These bronzing drops are specifically designed to complement deeper skin tones.

Key Points: 
  • These bronzing drops are specifically designed to complement deeper skin tones.
  • Nanobronze™ Deep is safe for all skin types and ideal for anyone looking for an instant sun-kissed glow without sun damage.
  • "Our original Nanobronze is beloved by so many but is less suitable for consumers with deeper skin tones.
  • Acting as a protective shield against pollution, these bronzing drops support the skin's barrier and reduce the appearance of redness.

The World's #1* dark spot serum brand, NIVEA, is now launching this scientific breakthrough in Canada: Power-Packed Formula Delivers Results in Just 2 Weeks*

Retrieved on: 
Wednesday, February 7, 2024
Dark, Serum, NIVEA, Ageing, Skin, Hyaluronic acid, Cosmetics

The culmination of 10 years of scientific research, NIVEA Luminous630® boasts unparalleled efficacy in lightening and reducing the look of dark spots.

Key Points: 
  • The culmination of 10 years of scientific research, NIVEA Luminous630® boasts unparalleled efficacy in lightening and reducing the look of dark spots.
  • This dual-action formula – the first of its kind in the mass market – makes the advanced results typically associated with luxury brands accessible to all consumers.
  • Users can expect to see visible results within two weeks* of consistent use, revealing a smoother and more radiant-looking complexion.
  • "We're thrilled about launching NIVEA Luminous630® in Canada and look forward to our consumers discovering the transformative potential of their skin."

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge

Retrieved on: 
Monday, February 5, 2024
SARS-CoV-2, COVID-19, SAN, Norovirus, Volatile organic compound, Vaxart, Animal, Disease, Immunoglobulin G, Vaccination, Infection, Immunoglobulin A, VOC, Serum, Development, Immunization, Vaccine

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the publication of preclinical non-human primate data demonstrating the potential of its COVID-19 vaccine to protect against multiple SARS-CoV-2 variants of concern (VOC)s. The data, which were previously presented at the International Congress of Mucosal Immunology 2022, are reported in the current issue of Vaccines.

Key Points: 
  • “The data published in Vaccines support the potential of our vaccine platform to stimulate potent mucosal cross-reactive IgA responses to multiple VOCs and reduce viral transmission.
  • All three vaccines induced neutralizing antibodies in both the peripheral and mucosal compartments, which was enhanced with a boost immunization.
  • Viral replication and infectious particle shedding were significantly reduced in immunized animals after challenge with beta variant SARS-CoV-2.
  • Vaxart believes these data support the potential for its vaccines to enhance mucosal responses and reduce community transmission, in addition to preventing severe disease.

EQS-News: Immunic to Participate in Investor and Scientific Conferences in February

Retrieved on: 
Monday, February 5, 2024
Abstract, Multiple sclerosis, MD, Research, Biotechnology, Serum, Communication, Cleveland Clinic

NEW YORK, February 1, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in February:

Key Points: 
  • NEW YORK, February 1, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in February:
    February 8: BioCapital Europe 2024.
  • Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, and Jessica Breu, Vice President Investor Relations and Communications, will attend this conference in Amsterdam and host one-on-one investor meetings.
  • The poster presentations will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Poster Title: Impact of Vidofludimus Calcium on Serum Neurofilament in Progressive MS: Data from the CALLIPER Interim Analysis
    Presenting Author: Robert J.

ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes

Retrieved on: 
Wednesday, January 31, 2024
ROS, Inflammation, Uric acid, Insulin resistance, Research, Obesity, Cardiovascular disease, Glucose, Type, OGTT, Hypertension, ASC, Therapy, Journal of Translational Medicine, Risk, Journal, Type 2 diabetes, Serum, Translational medicine, NLRP3, Oxidative stress, Inflammasome, Pharmaceutical industry

ZyVersa is developing Inflammasome ASC Inhibitor IC 100 which inhibits NLRP3 and other types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.

Key Points: 
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100 which inhibits NLRP3 and other types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.
  • In the paper titled, “Altered insulin secretion dynamics relate to oxidative stress and inflammasome activation in children with obesity and insulin resistance,” the authors conducted a case-controlled study of 132 children who were either lean or obese.
  • The authors concluded, “It is insulin response to an OGTT that identifies children with obesity suffering oxidative stress, and inflammasome activation more specifically.
  • “The research published in the Journal of Translational Medicine points to a significant role for inflammasome-mediated inflammation and oxidative stress in development of metabolic complications in obese children.

Uvax Bio Announces Dosing of First Participant in Phase 1 Clinical Trial Evaluating Two Vaccines to Prevent HIV-1 Infection

Retrieved on: 
Tuesday, January 30, 2024
AIDS, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, HIV-1, Subtypes of HIV, Animal, HIV, Computational biology, Safety, UFO, Immunization, Serum, Env, Vaccine

“UVAX-1107 and UVAX-1197 represent an advancement in HIV vaccine technology with industry-recognized innovations in our antigen design and delivery.

Key Points: 
  • “UVAX-1107 and UVAX-1197 represent an advancement in HIV vaccine technology with industry-recognized innovations in our antigen design and delivery.
  • Uvax Bio expects to report topline data from the Phase 1 trial in the fourth quarter of 2024.
  • The novel protein nanoparticle vaccine candidates are designed for active immunization and are intended to prevent HIV-1 infection.
  • Furthermore, preliminary screening assays demonstrated appreciable neutralization in serum when tested against a panel of primary HIV-1 isolates.